HitGen Inc. entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co. Ltd. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectively comprise over 1.2 trillion small, drug-like molecules to discover compounds that bind to certain targets that Daewoong needs to discover for new drug development.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.04 CNY | 0.00% | -5.78% | -13.01% |
24/04 | HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
23/02 | HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.01% | 72Cr | |
+8.29% | 11TCr | |
+10.21% | 10TCr | |
+0.70% | 2.23TCr | |
-11.90% | 2.24TCr | |
-5.24% | 1.91TCr | |
-37.36% | 1.8TCr | |
-5.17% | 1.79TCr | |
+7.70% | 1.43TCr | |
+37.65% | 1.25TCr |
- Stock Market
- Equities
- 688222 Stock
- News HitGen Inc.
- DAEWOONG PHARMACEUTICAL Co., Ltd and HitGen Inc. Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery